Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1993-09-30
1998-09-08
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241331, 4241381, 435 723, 435328, 435330, 5303873, 5303877, A61K 39395, A61K 3940, A61K 3942, G01N 33574
Patent
active
058041877
ABSTRACT:
An analogue peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixtures thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analogue peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the analogue peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analogue peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analogue peptide of this invention, monoclonal antibodies thereof, Fab, Fab', (Fab').sub.2, CDR, variable region, or analogues or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixtures thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.
REFERENCES:
patent: 4708930 (1987-11-01), Kortright
patent: 5075219 (1991-12-01), Ceriani et al.
patent: 5077220 (1991-12-01), Ceriani et al.
Harris et al. Tibtech vol. 11, 1993, p. 42 Morrison et al. p. 187 Genetic engineering Annals of N.Y. Acad. 1988.
Vitetta et al. vol. 238 Science p. 1098, 1987.
Neuberger et al. Nature vol. 312 1984 p. 604.
Hird et al. Genes and Cancer Carney et al. ed. 1990 p. 183.
Cunningham Tibtech vol. 10, 1992 p. 112.
Couto, J.R., et al. "Humanization of KC4G3, an Anti-Human Carcinoma Antibody", Hybridoma, vol. 13, No. 3, pp. 215-219, 1994.
Peterson, J.A., et al., "Biochemical and Histological Characterization of Antigens Preferentially Expressed on the Surface and Cytoplasm of Breast Carcinoma Cells Identified by Monoclonal Antibodies Against the Human Milk Fat Globule", Hybridoma 9:221-235 (1990).
Davies, D.R. and Padlan, E.A., "Antibody-Antigen Complexes", Annu. Rev. Biochem. 59:439-73 (1990).
Riechmann, L., et al., "Reshaping Human Antibodies for Therapy", Nature 332:323-327 (1988).
Varhoeyen, et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", Science 239: 1534-1536 (Mar. 23, 1988).
Tempest, et al., "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Synctial Virus Infection In Vivo", Biotechnology 9: 266-271 (Mar. 1991).
Kettleborough et al., (Protein Eng. 4:773-783 (1991) Humanization of a mouse monoclonal . . .
Eigenbrot et al., (Proteins: Structure, Function and Genetics 18:49-62 (1994) X-ray Structures of . . .
Bowie et al. (Science, vol. 24: 1306-1310) Deciphering the Message in Protein Sequences . . . (1990).
Co and Queen, Nature 351:501-502 (1991) Humanized antibodies for therapy.
Presta et al., Jour. of Immuno. 151:2623-2632 (1993) Humanization of an antibody directed against . . .
Davies & Padlan, (Current Biology, 2:254-256 (1992) Twisting into Shape.
Richard Friend, (Nature 326:335 (1987) Polymers from the Soviet Union.
Dennis R. Burton (Elsevier Science Publishers, Ltd (UK) pp. 64-68 (1990) Antibody: the.
Baggiolini & Wymann (Elsevier Science Publishers, Ltd. (UK) p. 69 (1990) Turning on the respiratory . . .
Lisa A. Steiner, (Bioscience Reports 5:973-989 (1983) Immunoglobulin disulfide bridges: Theme . . .
Huber & Bennett, (Nature 326:334 (1987) Antibody -antigen flexibility.
Fischmann et al., (J. Bio. Chem., 266:1291512920 (1991) Crystallographic Refinement of the Three . . .
Brady et al., (J. Mol. Biol. 227:253-264 (1992) Crystal Structure of a Chimeric Fab' Fragment of an . . .
Bhat et al., Nature 347:483-485 (1990) Small rearrangements in structures of Fv and Fab fragments . . .
Bhat et al., Proc. Natl. Acd. Sci (USA) 91:1089-1093 Bound water molecules and conformational . . .
Peter J. Delves, Encyclopedia of Immunology, Academic Press, p. 207 (Avidity) (1992).
Ceriani Roberto L.
Couto Fernando J. R. do
Peterson Jerry A.
Cancer Research Fund of Contra Costa
Eyler Y.
Scheiner Toni R.
LandOfFree
Modified antibodies with human milk fat globule specificity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified antibodies with human milk fat globule specificity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified antibodies with human milk fat globule specificity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1279599